ESH ALL 2021 | Latest advancements in childhood leukemias
Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, outlines the latest advances in the development of new therapies for childhood leukemia. CAR T-cell therapy has shown tremendous progress with approved products and the rapid and continued development of new CAR T-cells in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Driven by the recognition that many mutations that cause childhood leukemias are in genes involved in the regulation of gene expression through chromatin, therapies targeting epigenetic mechanisms are under development and preliminary data from clinical trials seem promising. Dr Armstrong concludes that advances in the CAR-T and epigenetic space for pediatric disease will also impact adult leukemias. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Sponsored Research: Syndax Pharmaceuticals, Novartis, Janssen.
Scientific Advisory Board: C4 Therapeutics, Imago Biosciences, Neomorph Inc.
